Company Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.
Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.
The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.
It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox.
Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 2000 |
| IPO Date | Apr 11, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Michael Andriole |
Contact Details
Address: 2505 Meridian Parkway, Suite 100 Durham, North Carolina 27713 United States | |
| Phone | 919-806-1074 |
| Website | chimerix.com |
Stock Details
| Ticker Symbol | CMRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001117480 |
| CUSIP Number | 16934W106 |
| ISIN Number | US16934W1062 |
| Employer ID | 33-0903395 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael T. Andriole M.B.A. | Chief Executive Officer, President and Director |
| Dr. Michael A. Alrutz J.D., Ph.D. | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer |
| Michelle LaSpaluto | Chief Financial Officer |
| Thomas J. Riga | Chief Operating and Commercial Officer |
| David Jakeman CPA | Vice President of Accounting and Finance |
| Dr. Joshua E. Allen Ph.D. | Chief Technology Officer |
| Dr. Roy W. Ware M.B.A., Ph.D. | Chief Manufacturing Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Aug 13, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 144 | Filing |
| Jul 3, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| May 3, 2024 | EFFECT | Notice of Effectiveness |
| May 1, 2024 | 10-Q | Quarterly Report |
| May 1, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |